期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.616837
关键词
VEGF-A (vascular endothelial growth factor-A); effector T-cells; regulatory T (Treg) cells; tumor; anti-angiogenic therapy; immunosuppression; immune check point inhibitor (ICI)
类别
资金
- ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante, National Alliance for Life Sciences Health)
- Association pour la Recherche contre le Cancer
- Canceropole Ile de France/INCa [2017-1-EMERG-74-INSERM-5-1]
- SIRIC CARPEM
- Labex Immuno-oncology
- Ligue contre le Cancer
VEGF-A plays a central role in tumor angiogenesis and is also an immunosuppressive factor, modulating immune cells and affecting regulatory T cells. Anti-angiogenic agents targeting VEGF-A/VEGFR can limit tumor-induced immunosuppression and enhance treatment efficacy.
Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis. Several studies showed that VEGF-A is also an immunosuppressive factor. In tumor-bearing hosts, VEGF-A can modulate immune cells (DC, MDSC, TAM) to induce the accumulation of regulatory T-cells while simultaneously inhibiting T-cell functions. Furthermore, VEGFR-2 expression on activated T-cells and FoxP3(high) regulatory T-cells also allow a direct effect of VEGF-A. Anti-angiogenic agents targeting VEGF-A/VEGFR contribute to limit tumor-induced immunosuppression. Based on interesting preclinical studies, many clinical trials have been conducted to investigate the efficacy of anti-VEGF-A/VEGFR treatments combined with immune checkpoint blockade leading to the approvement of these associations in different tumor locations. In this review, we focus on the impact of VEGF-A on immune cells especially regulatory and effector T-cells and different therapeutic strategies to restore an antitumor immunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据